Yale researchers solve structure of the ribosome: groundbreaking achievement 'like climbing Mount Everest'

In a landmark achievement, Yale researchers have determined the atomic structure of the ribosome's large subunit, paving the way for more effective drugs to fight infection.

The findings, published in two separate articles in this week's issue of the journal Science, were derived in Yale laboratories led by Thomas Steitz, the Eugene Higgins Professor of Molecular Biophysics and Biochemistry and investigator at the Howard Hughes Medical Institute, and Peter Moore, the Eugene Higgins Professor of Chemistry.

"This is like climbing Mt. Everest or running the four minute mile," Steitz said. "We have solved the structure of the ribosome's large subunit, which is the largest unique structure determined. We have established that the ribosome is a ribozyme, an enzyme in which catalysis is done by RNA, not protein."

The ribosome is the cellular structure responsible for synthesizing protein molecules in all organisms. In addition to enhancing the understanding of protein synthesis, the research offers new clues about evolution and has significant medical implications because the ribosome is a major target for antibiotics.

Many antibiotics cure disease by selectively inhibiting the protein synthesizing activity of large ribosomal subunits in disease-causing bacteria, while leaving human ribosomes alone. Unfortunately, over the years, many bacteria have become resistant

to these agents, and the possibility exists that the devastating bacterial diseases that were brought under control by antibiotics in the 1940s and 1950s will once again become scourges.

"Now that we know the structure of the large ribosomal subunit," Steitz said, "we can determine its exact structure with antibiotics bound to it." The same methods of "structure-based drug design" that led to the development of HIV protease inhibitors for AIDS can now be used on the ribosome, which is 100 times larger.

"The information that emerges should enable pharmaceutical co

Contact: Karen Peart
Yale University

Page: 1 2

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. $7.5 Million grant to Yale researchers for role of viruses in cancer
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Joslin researchers clarify mechanisms for beta-cell formation
6. Virginia Tech researchers to release findings on Smith River Project
7. Molecular motor myosin VI moves hand over hand, researchers say
8. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
9. Emory researchers map structure of anti-cancer molecule
10. Leukemia stem cells identified by Stanford researchers
11. EURYI Award given for the first time to 25 young European researchers

Post Your Comments:

(Date:3/2/2020)... ... March 02, 2020 , ... Rigaku ... Conference on Analytical Chemistry and Applied Spectroscopy ( Pittcon 2020 ), being held ... world’s leading annual conference and exposition on laboratory science, attracting attendees from industry, ...
(Date:2/28/2020)... Kan. (PRWEB) , ... February ... ... proudly announces that its patent-pending Rebound PRP™ and Rebound PRF® devices are ... university-validated a new generation of regenerative medical devices, that will provide the ...
(Date:2/28/2020)... ... ... Regen Suppliers is now offering the top FDA Cleared threads available on ... not only one of the only FDA Cleared options available, there are fifteen different ... popularity, as they represent an excellent nonoperative method of reducing wrinkles and helping individuals ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... ... March 31, 2020 , ... ... a method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables that decreases ... volumes, increased samples per run, and standard, affordable laboratory equipment, a qualitative ...
(Date:3/19/2020)... Md. (PRWEB) , ... March ... ... a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company ... cell therapies for ovarian cancer and other solid tumor indications. The collaboration ...
(Date:3/10/2020)... ... March 10, 2020 , ... ... cold chain biopharmaceutical engineering firm, is pleased to announce the addition of ... combination medical device qualification and validation in the biopharmaceutical cold chain. He ...
(Date:3/3/2020)... ... 2020 , ... Ideal Implant Incorporated Founder and CEO, Robert ... the IMCAS Innovation Shark Tank 2020 in Paris, France in January. The international ... science industries that promise to revolutionize medical practices in their fields. , ...
Breaking Biology Technology:
Cached News: